C.Q. Pharmaceutical Holding Co., Ltd.'s (SZSE:000950) Last Week's 5.5% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
C.Q. Pharmaceutical Holding Co., Ltd.'s (SZSE:000950) Last Week's 5.5% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Key Insights
主要见解
- Significant control over C.Q. Pharmaceutical Holding by private companies implies that the general public has more power to influence management and governance-related decisions
- The top 2 shareholders own 55% of the company
- Using data from company's past performance alongside ownership research, one can better assess the future performance of a company
- 私人公司对重药控股的重要控制意味着普通公众有更多的影响和管理权决策力。
- 前2大股东拥有该公司的55%股份。
- 通过公司过去的业绩数据和股权研究,人们可以更好地评估一家公司的未来表现。
Every investor in C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) should be aware of the most powerful shareholder groups. We can see that private companies own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
所有重药控股股东应该注意最强大的股东群体。我们可以看到私人公司拥有该公司57%的股份所有权。也就是说,如果股票上涨,该股东群体将获益最多(或者在市场下跌时会蒙受最大损失)。
And last week, private companies endured the biggest losses as the stock fell by 5.5%.
上周,私人公司遭受了市场下跌5.5%的最大损失。
Let's take a closer look to see what the different types of shareholders can tell us about C.Q. Pharmaceutical Holding.
让我们更仔细地了解一下不同类型的股东对重药控股所代表者什么意义。
What Does The Institutional Ownership Tell Us About C.Q. Pharmaceutical Holding?
机构持股对重药控股公司有什么提醒?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。
C.Q. Pharmaceutical Holding already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of C.Q. Pharmaceutical Holding, (below). Of course, keep in mind that there are other factors to consider, too.
重药控股公司已拥有股份登记制度机构。他们在公司中拥有高显著的股权,这意味着专业投资者之间的信誉可信。但是我们不能仅仅依靠这一事实,因为就像每个人一样,机构有时会做出糟糕的投资。如果两个大型机构投资者同时试图抛售一家股票,很常见的是其股价会大幅下跌。因此,了解重药控股的过去收益轨迹也很值得一看(如下所示)。当然,还需要考虑其他的因素。
Hedge funds don't have many shares in C.Q. Pharmaceutical Holding. Our data shows that Chongqing Pharmaceutical Health Industry Co., Ltd. is the largest shareholder with 38% of shares outstanding. Chongqing City Construction Investment (Group) Co.,Ltd is the second largest shareholder owning 16% of common stock, and Chongqing Yufu Capital Equity Investment Fund Management Co. holds about 3.2% of the company stock.
对于重药控股,对冲基金并没有很多的股份。我们的数据显示,重庆市药品保健行业有限公司是最大的股东,拥有该公司38%的流通股,其次是重庆市城市建设投资(集团)有限公司,持有16%的普通股,重庆宇富资本股权投资基金管理有限公司持有该公司约3.2%的股份。
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 55% stake.
股东登记簿的更详细研究显示,前两名股东中有2人持有该公司约55%的股份。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.
虽然研究公司的机构持股可以增加研究价值,但研究分析师建议以更深入地了解股票的预期表现也是一个好习惯。该股票的一些分析人士需要更多的关注时间。
Insider Ownership Of C.Q. Pharmaceutical Holding
重药控股的内部所有者权益
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
虽然内部人员的精确定义可能具有主观性,但几乎所有人都认为董事会成员是内部人员。管理层最终向董事会负责。然而,如果经理是创始人或CEO,那么他们成为执行董事会成员并不罕见。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部人士持股是一件好事。但是,在某些情况下,它会使其他股东更难以对董事会的决定进行问责。
Our data suggests that insiders own under 1% of C.Q. Pharmaceutical Holding Co., Ltd. in their own names. However, it's possible that insiders might have an indirect interest through a more complex structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥5.3m worth of shares (at current prices). It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我们的数据表明,内部人以自己的名义拥有不到1%的重药控股股份。然而,内部人可能通过更复杂的结构间接持有利益。这是一家相当大的公司,董事会成员可能拥有公司的大量利益,而比例相对较低。在这种情况下,他们拥有价值约为530万元人民币(按当前价格)的股份。看到内部持股至少有一定比例总是很好的,但是值得检查这些内部人是否在抛售。
General Public Ownership
一般大众所有权
The general public, who are usually individual investors, hold a 30% stake in C.Q. Pharmaceutical Holding. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
普通公众通常是个人投资者,持有重药控股公司30%的股份。虽然这种所有权规模可能不足以影响其喜好的政策决策,但仍然可以在公司政策上发挥集体影响。
Private Company Ownership
私有公司的所有权
Our data indicates that Private Companies hold 57%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我们的数据表明,私人公司持有该公司上市股份的57%。可能值得更深入地研究一下。如果关联方如内部人员在这些私营公司之一拥有利益,那么这应该在年度报告中披露。私人公司也可能对公司具有战略兴趣。
Public Company Ownership
上市公司所有权
It appears to us that public companies own 3.9% of C.Q. Pharmaceutical Holding. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
在我们看来,上市公司拥有重药控股公司的3.9%。很难确定,但这表明它们具有交织的商业利益。这可能是一个战略性利益,因此值得密切关注所有权的变化。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for C.Q. Pharmaceutical Holding (1 makes us a bit uncomfortable) that you should be aware of.
尽管考虑公司的不同持股群体是十分重要的,但还有其他更重要的因素。例如,我们已经识别出重药控股公司的三个警告特征(其中有一个让我们有些不安) ,你应该注意。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com